International Clinical Trial: A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444450) titled 'A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec' on Feb. 26.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Biogen

Condition: Muscular Atrophy, Spinal

Intervention: Drug: Salanersen

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: September 4, 2026

Target Sampl...